FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

Media Formats

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Comments

Overview
The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Released May 30, 2017.

Recommended

Details

Comments

Overview
The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Released May 30, 2017.